Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood–Derived Products Marketed as Stem Cell Therapies

Authors:

Abstract
Many clinics marketing stem cell products as treatment for joint diseases, sports injuries, and chronic pain opened in recent years1,2 despite warnings from the US Food and Drug Administration (FDA) that stem cell products for these and other indications have not been proven safe or effective.3 Recently, there has been an increase in marketing of unapproved stem cell products to prevent and treat COVID-19.4,5 The only FDA-approved stem cell products are derived from umbilical cord blood and are used to treat certain cancers and disorders of the hematopoietic system, such as leukemias, lymphomas, and sickle cell disease.3,6,7 The FDA has not approved stem cell products to treat any other diseases or conditions, such as osteoarthritis or aging. Generally, an unapproved stem cell product should be administered to patients only if there is an Investigational New Drug Application (IND) in effect for that product with FDA.